Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neurimmune Holding

Request full access

A biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases

Zurich, SwitzerlandFounded 2006Biotech & Life Sciences

About Neurimmune Holding

Neurimmune is a biopharmaceutical company focused on translating human immune memory into antibody therapeutics. The company operates in the biopharmaceutical market, primarily targeting neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). Neurimmune's business model involves discovering and developing antibody-based therapies and then licensing these discoveries to larger pharmaceutical companies for further development and commercialization. For instance, Neurimmune discovered aducanumab, an antibody for Alzheimer's disease, which was licensed to Biogen for further development and submission to the U.S. Food and Drug Administration (FDA). The company generates revenue through licensing agreements, research collaborations, and milestone payments from its partners. Neurimmune serves a global market, collaborating with both academic institutions and industry partners to advance its pipeline of therapeutic candidates. The company's innovative approach leverages the natural immune response to create treatments that can potentially transform the lives of patients with debilitating diseases.

Source: Dealroom company data

Neurimmune Holding in the Zurich ecosystem

Live from Dealroom

The Neurimmune Holding office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Biogen
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Neurimmune Holding on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.